Vladimir Wsol
8PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Oct 27, 2022
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux.Lucie Čermáková, Jakub Hofman, Lenka Laštovičková
|Aug 16, 2022
Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.Anselm Morell, Youssif Budagaga, Dimitrios Vagiannis
|Dec 16, 2020
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.Anselm Morell, Lucie Čermáková, Eva Novotná
|Oct 29, 2020
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.Tássia S Tavares, Jakub Hofman, Alžběta Lekešová
|Oct 07, 2020
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.Anselm Morell, Eva Novotná, Jaroslav Milan
|Jun 27, 2020
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?Eva Novotná, Anselm Morell, Neslihan Büküm
Pageof 2
